Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology
The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …
Cancer nanomedicine: progress, challenges and opportunities
J Shi, PW Kantoff, R Wooster, OC Farokhzad - Nature reviews cancer, 2017 - nature.com
The intrinsic limits of conventional cancer therapies prompted the development and
application of various nanotechnologies for more effective and safer cancer treatment …
application of various nanotechnologies for more effective and safer cancer treatment …
What went wrong with anticancer nanomedicine design and how to make it right
The three design criteria of anticancer nanomedicines to improve anticancer efficacy and to
reduce toxicity have been debated for decades:(1) Nanomedicines increase drug …
reduce toxicity have been debated for decades:(1) Nanomedicines increase drug …
[HTML][HTML] Nanocarrier-based drug combination therapy for glioblastoma
M Zhao, D van Straten, MLD Broekman, V Préat… - Theranostics, 2020 - ncbi.nlm.nih.gov
The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …
Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma
MS Lionakis, K Dunleavy, M Roschewski… - Cancer cell, 2017 - cell.com
Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR)
signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is …
signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is …
Nanomedicine for brain cancer
CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology
Cancer nanotherapeutics are progressing at a steady rate; research and development in the
field has experienced an exponential growth since early 2000's. The path to the …
field has experienced an exponential growth since early 2000's. The path to the …
Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier
DB Vieira, LF Gamarra - International journal of nanomedicine, 2016 - Taylor & Francis
This review summarizes articles that have been reported in literature on liposome-based
strategies for effective drug delivery across the blood–brain barrier. Due to their unique …
strategies for effective drug delivery across the blood–brain barrier. Due to their unique …
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in …
H Lee, AF Shields, BA Siegel, KD Miller, I Krop… - Clinical Cancer …, 2017 - AACR
Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through
enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its …
enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its …
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort
of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the …
of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the …